NEW YORK, May 5, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding SLM Corporation (NASDAQ: SLM), Visa Inc. (NYSE: V), MasterCard Inc. (NYSE: MA), Willis Group Holdings PLC (NYSE: WSH) and Johnson & Johnson (NYSE: JNJ). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2019-100free.
--
SLM Corporation Analyst Notes
On May 1, 2014, shares of SLM Corporation (Sallie Mae), plummeted 64.97% to settle at $9.02. According to an article on NASDAQ dated May 1, 2014, the stock fell after the company completed the spin off its Navient loan-management, servicing and asset-recovery business. On April 10, 2014, the Board of Directors of Sallie Mae unanimously approved the separation of its loan management, servicing and asset recovery business, known as Navient, from its consumer banking business. Sallie Mae Bank's consumer banking business remains under the Sallie Mae brand. The full analyst notes on Sallie Mae are available to download free of charge at:
http://www.analystsreview.com/2019-SLM-05May2014.pdf
--
Visa Inc. Analyst Notes
On April 24, 2014, Visa Inc. (Visa) released its Q2 FY 2014 earnings (period ended March 31, 2014). The Company reported Q2 FY 2014 total operating revenue of $3.2 billion, up 6.9% YoY. According to the Company, the growth in operating revenues was driven by strong growth in service revenues, data processing revenues and international transaction revenues. Q2 FY 2014 net income stood at $1.6 billion, compared to a net income of $1.3 billion in Q2 FY 2013. Adjusted EPS came in at $2.20, beating the consensus EPS forecast by $0.02 of 31 analysts polled by Bloomberg. For FY 2014, the Company expects revenue growth between 10% and 11% and annual free cash flow of about $5 billion. The full analyst notes on Visa are available to download free of charge at:
http://www.analystsreview.com/2019-V-05May2014.pdf
--
MasterCard Inc. Analyst Notes
On April 29, 2014, MasterCard Inc. (MasterCard) announced that the Company has signed an exclusive agreement with Portuguese football legend Deco to be the Official Player Mascot Manager for the UEFA Champions League Final 2014. The Company informed that as the official sponsor of the UEFA Champions League, MasterCard is giving a chance to 22 lucky children across Europe to become the Official Player Mascots for the UEFA Champions League Final in Lisbon on May 24, 2014 through "Player Mascot Training Camp" that features mini-lookalikes of a number of legendary past UEFA Champions League winning players. Further, the guide will help the chosen mascots enjoy an incredible experience on May 24, 2014. Javier Perez, President, MasterCard said, "Being a Player Mascot in European football's showpiece event is the closest that any kid can get to living the priceless experience of being a footballer in the UEFA Champions League Final." The full analyst notes on MasterCard are available to download free of charge at:
http://www.analystsreview.com/2019-MA-05May2014.pdf
--
Willis Group Holdings PLC Analyst Notes
On May 1, 2014, Willis Group Holdings PLC (Willis) announced the appointment of Jeroen Everling as CEO of Willis Netherlands (Willis BV) effective June 1, 2014. The Company informed that Jeroen Everling will succeed Alistair Lester, interim CEO, who will continue to support Willis BV in a Non-Executive role. The Company stated that Everling was previously working with Aon Risk Solutions as an Executive Director since 2006. Commenting on the appointment, Alberto Gallego, Regional CEO of Willis Western Europe, said, "Jeroen's broad experience in a range of both domestic and international roles is the perfect background for leading a strong team in this strategically important and mature market, where we are uniquely positioned for growth." The full analyst notes on Willis are available to download free of charge at:
http://www.analystsreview.com/2019-WSH-05May2014.pdf
--
Johnson & Johnson Analyst Notes
On April 25, 2014, Janssen-Cilag International NV (Janssen), a subsidiary of Johnson & Johnson (Johnson & Johnson), announced that its VOKANAMET® (a fixed-dose therapy combining canagliflozin and immediate release metformin hydrochloride in a single tablet) has been approved by European Commission (EC) in the European Union (EU), for the treatment of adults with type II diabetes mellitus to improve glycaemic control. Canagliflozin as a single agent was approved as INVOKANA® in the European Union (EU) in November 2013. Following the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency, in February 2014, the EC approved the VOKANAMET®. The full analyst notes on Johnson & Johnson are available to download free of charge at:
http://www.analystsreview.com/2019-JNJ-05May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
